Healthcare Professionals
Why KOGENATE® Bayer?
Patient information
You can download the following files in PDF format :
Summary of Product Characteristics Prescribing Information Patient Information LeafletKOGENATE® Bayer is a FVIII concentrate product produced by recombinant DNA technology for use in the treatment of haemophilia A.
KOGENATE® Bayer is purified and formulated without albumin and stabilised with sucrose. In addition, the KOGENATE® Bayer process includes two viral inactivation steps, a solvent/detergent process and a high salt hold step.
Bayer has a well documented record of safety and efficacy derived from 20 years of clinical experience with recombinant FVIII, equating to over 10 billion units infused without a confirmed viral or prion transmission (Data on file, KGB01).
lowest published inhibitor formation in PUPs/MTPs 1,2
Pivotal studies excluding post marketing.
Data from non-comparative studies
confirmed cases of viral or prion transmission 3
in over 20 years and 10 billion units infused*
*Combined history of Kogenate® and KOGENATE® Bayerr
compared to therapy on demand 4,27
To examine the evidence on KOGENATE Bayer please click the relevant link below:
Inhibitors Safety & Manufacturing Efficacy Data Product Convenience Prophylaxis Product Support
Safety Butterfly
For more
information on the
safety butterfly > click here
References
1. Kreuz W et al. Thromb Haemost 2005;93:457-467
2. Courter GG and Bedrosian CL. Semin Hematol 2001;38(2)(Suppl 4):52-59
3. Data on file. KOGENATE® Bayer 0143 (Bayer HealthCare 2010)
4. Manco-Johnson MJ et al. N Engl J Med 2007;357:535-544
27. Collins P et al. J Thromb Haemost 2010;8:85-89
Produced by Bayer. This website is intended for HealthCare professionals.
Date of preparation: December 2010
UK.PH.HN.KOG.2010.250.13.6